A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo

International Journal of Cancer

Volumn 122, Issue 11, 2008, Pages 2405-2413

  Villa, Alessandra ^a   Trachsel, Eveline ^a   Kaspar, Manuela ^a   Schliemann, Christoph ^a   Sommavilla, Roberto ^a   Rybak, Jascha N ^a   Rösli, Christoph ^a   Borsi, Laura ^b   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

EDA domain of fibronectin; Oncofetal fibronectin; scFV antibody fragments; Vascular tumor targeting

Indexed keywords

FIBRONECTIN; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B7; MONOCLONAL ANTIBODY D5; MONOCLONAL ANTIBODY F8;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; DRUG SPECIFICITY; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ALTERNATIVE SPLICING; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA PRIMERS; FIBRONECTINS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STRUCTURE, TERTIARY; TERATOCARCINOMA; TESTICULAR NEOPLASMS; TISSUE DISTRIBUTION;

EID: 42549099073     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23408     Document Type: Article

References (63)

1. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-46.
2. Rybak JN, Trachsel E, Scheuermann J, Neri D. Ligand-based vascular targeting of disease. Chem Med Chem 2007;2:22-40.
3. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006;5:147-59.
4. Weiner LM, Adams GP. New approaches to antibody therapy. Oncogene 2000;19:6144-51.
5. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-57.
6. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987;6:2337-42.
7. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994;59:612-18.
8. Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, Winter G, Zardi L. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer 1996;68:397-405.
9. Castellani P, Borsi L, Carnemolla B, Biro A, Dorcaratto A, Viale GL, Neri D, Zardi L. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 2002;161:1695-700.
10. Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1994;59:11-16.
11. Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006;118:1331-9.
12. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998;273:21769-76.
13. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L. Selective target-ing of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002;102:75-85.
14. Wyss MT, Spaeth N, Biollaz G, Pahnke J, Alessi P, Trachsel E, Treyer V, Weber B, Neri D, Buck A. Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis. J Nucl Med 2007;48:608-14.
15. Spaeth N, Wyss MT, Pahnke J, Biollaz G, Trachsel E, Drandarov K, Treyer V, Weber B, Neri D, Buck A. Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19). Nucl Med Biol 2006;33:661-6.
16. Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigtervan Walsum M, Zardi L, van Dongen GA. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 2006;47:1127-35.
17. Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, Hilger CS, Cyr JE, Dinkelborg LM. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 2005;11:7053s-7063s.
18. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-9.
19. Muro AF, Caputi M, Pariyarath R, Pagani F, Buratti E, Baralle FE. Regulation of fibronectin EDA exon alternative splicing: possible role of RNA secondary structure for enhancer display. Mol Cell Biol 1999;19:2657-71.
20. Borsi L, Castellani P, Allemanni G, Neri D, Zardi L. Preparation of phage antibodies to the ED-A domain of human fibronectin. Exp Cell Res 1998;240:244-51.
21. Viti F, Nilsson F, Demartis S, Huber A, Neri D. Design and use of phage display libraries for the selection of antibodies and enzymes. Methods Enzymol 2000;326:480-505.
22. Giovannoni L, Viti F, Zardi L, Neri D. Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening. Nucleic Acids Res 2001;29:E27.
23. Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol 1992;227:776-98.
24. Cox JP, Tomlinson IM, Winter G. A directory of human germ-line V K segments reveals a strong bias in their usage. Eur J Immunol 1994;24:827-36.
25. Chan S, Gabra H, Hill F, Evan G, Sikora K. A novel tumour marker related to the c-myc oncogene product. Mol Cell Probes 1987;1:73-82.
26. Silacci M, Brack S, Schirru G, Marlind J, Ettorre A, Merlo A, Viti F, Neri D. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 2005;5:2340-50.
27. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006;12:3200-8.
28. Silacci M, Brack SS, Spath N, Buck A, Hillinger S, Arni S, Weder W, Zardi L, Neri D. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 2006;19:471-8.
29. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999;94:192-8.
30. Fraker PJ, Speck JC, Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenyl-glycoluril. Biochem Biophys Res Commun 1978;80:849-57.
31. Salacinski PR, McLean C, Sykes JE, Clement-Jones VV, Lowry PJ. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3α,6α-diphenyl glycoluril (Iodogen). Anal Biochem 1981;117:136-46.
32. Kuhne SA, Hawes WS, La Ragione RM, Woodward MJ, Whitelam GC, Gough KC. Isolation of recombinant antibodies against EspA and intimin of Escherichia coli O157:H7. J Clin Microbiol 2004;42:2966-76.
33. Ettorre A, Rosli C, Silacci M, Brack S, McCombie G, Knochenmuss R, Elia G, Neri D. Recombinant antibodies for the depletion of abundant proteins from human serum. Proteomics 2006;6:4496-505.
34. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993;90:6444-8.
35. Kortt AA, Dolezal O, Power BE, Hudson PJ. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 2001;18:95-108.
36. Bestagno M, Occhino M, Corrias MV, Burrone O, Pistoia V. Recombinant antibodies in the immunotherapy of neuroblastoma: perspectives of new developments. Cancer Lett 2003;197:193-8.
37. Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962-9.
38. Berstine EG, Hooper ML, Grandchamp S, Ephrussi B. Alkaline phosphatase activity in mouse teratoma. Proc Natl Acad Sci USA 1973;70:3899-903.
39. Tweardy DJ, Caracciolo D, Valtieri M, Rovera G. Tumor-derived growth factors that support proliferation and differentiation of normal and leukemic hemopoietic cells. Ann N Y Acad Sci 1987;511:30-8.
40. Klein G, Giovanella B, Westman A, Stehlin JS, Mumford D. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 1975;5:319-34.
41. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
42. Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 1999;79:965-70.
43. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, Buchner T, Berdel WE, Mesters RM. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95:2637-44.
44. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999;59:347-52.
45. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998;58:485-90.
46. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, Gobert M, Conrath K, Muyldermans S, De Baetselier P, Revets H. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002;98:456-62.
47. Birchler M, Viti F, Zardi L, Spiess B, Neri D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat Biotechnol 1999;17:984-8.
48. Fabbrini M, Trachsel E, Soldani P, Bindi S, Alessi P, Bracci L, Kosmehl H, Zardi L, Neri D, Neri P. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int J Cancer 2006;118:1805-13.
49. Demartis S, Tarli L, Borsi L, Zardi L, Neri D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 2001;28:534-9.
50. Berndorff D, Borkowski S, Moosmayer D, Viti F, Muller-Tiemann B, Sieger S, Friebe M, Hilger CS, Zardi L, Neri D, Dinkelborg LM. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med 2006;47:1707-16.
51. Marty C, Odermatt B, Schott H, Neri D, Ballmer-Hofer K, Klemenz R, Schwendener RA. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer 2002;87:106-12.
52. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61:711-16.
53. Heinis C, Alessi P, Neri D. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy. Biochemistry 2004;43:6293-303.
54. Melkko S, Halin C, Borsi L, Zardi L, Neri D. An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int J Radiat Oncol Biol Phys 2002;54:1485-90.
55. Niesner U, Halin C, Lozzi L, Gunthert M, Neri P, Wunderli-Allenspach H, Zardi L, Neri D. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002;13:729-36.
56. Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002;99:1659-65.
57. Menrad A, Menssen HD. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 2005;9:491-500.
58. Halin C, Niesner U, Villani ME, Zardi L, Neri D. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int J Cancer 2002;102:109-16.
59. Gafner V, Trachsel E, Neri D. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 2006;119:2205-12.
60. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002;20:264-9.
61. Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor α. Cancer Res 2003;63:3202-10.
62. Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H, Zardi L, Neri D. Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy. Int J Cancer 2005;116:304-13.
63. Trachsel E, Bootz F, Silacci M, Kaspar M, Kosmehl H, Neri D. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 2007;9:R9.